 | • レポートコード：GIR-105X13770 • 出版社/出版日： / 2021年5月 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：Pharma & Healthcare |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、予防的HIV治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。予防的HIV治療薬の種類別市場規模（ヌクレオシド/ヌクレオチド逆転写酵素阻害剤（NRTI）、インテグラーゼ阻害剤）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・予防的HIV治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Gilead Sciences、Merck、Mylan、Cipla、Bristol-Myers Squibb、Roche ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：ヌクレオシド/ヌクレオチド逆転写酵素阻害剤（NRTI）、インテグラーゼ阻害剤 ・用途別分析2016年-2026年：病院薬局、小売薬局、オンライン薬局 ・予防的HIV治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・予防的HIV治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・予防的HIV治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・予防的HIV治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・予防的HIV治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Prophylactic HIV Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Prophylactic HIV Drug size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Prophylactic HIV Drug market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Prophylactic HIV Drug market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
Integrase Inhibitor
Market segment by Application can be divided into
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
The key market players for global Prophylactic HIV Drug market are listed below:
Gilead Sciences
Merck
Mylan
Cipla
Bristol-Myers Squibb
Roche
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
1 Market Overview
1.1 Prophylactic HIV Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Prophylactic HIV Drug Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
1.2.3 Integrase Inhibitor
1.3 Market Analysis by Application
1.3.1 Overview: Global Prophylactic HIV Drug Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Global Prophylactic HIV Drug Market Size & Forecast
1.4.1 Global Prophylactic HIV Drug Sales in Value (2016-2026))
1.4.2 Global Prophylactic HIV Drug Sales in Volume (2016-2026)
1.4.3 Global Prophylactic HIV Drug Price by Type (2016-2026) & (USD/Unit)
1.5 Global Prophylactic HIV Drug Production Capacity Analysis
1.5.1 Global Prophylactic HIV Drug Total Production Capacity (2016-2026)
1.5.2 Global Prophylactic HIV Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Prophylactic HIV Drug Market Drivers
1.6.2 Prophylactic HIV Drug Market Restraints
1.6.3 Prophylactic HIV Drug Trends Analysis
2 Manufacturers Profiles
2.1 Gilead Sciences
2.1.1 Gilead Sciences Details
2.1.2 Gilead Sciences Major Business
2.1.3 Gilead Sciences Prophylactic HIV Drug Product and Services
2.1.4 Gilead Sciences Prophylactic HIV Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 Merck
2.2.1 Merck Details
2.2.2 Merck Major Business
2.2.3 Merck Prophylactic HIV Drug Product and Services
2.2.4 Merck Prophylactic HIV Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 Mylan
2.3.1 Mylan Details
2.3.2 Mylan Major Business
2.3.3 Mylan Prophylactic HIV Drug Product and Services
2.3.4 Mylan Prophylactic HIV Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.4 Cipla
2.4.1 Cipla Details
2.4.2 Cipla Major Business
2.4.3 Cipla Prophylactic HIV Drug Product and Services
2.4.4 Cipla Prophylactic HIV Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.5 Bristol-Myers Squibb
2.5.1 Bristol-Myers Squibb Details
2.5.2 Bristol-Myers Squibb Major Business
2.5.3 Bristol-Myers Squibb Prophylactic HIV Drug Product and Services
2.5.4 Bristol-Myers Squibb Prophylactic HIV Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.6 Roche
2.6.1 Roche Details
2.6.2 Roche Major Business
2.6.3 Roche Prophylactic HIV Drug Product and Services
2.6.4 Roche Prophylactic HIV Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Prophylactic HIV Drug Sales by Manufacturer
3.1 Global Prophylactic HIV Drug Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Prophylactic HIV Drug Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Prophylactic HIV Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Prophylactic HIV Drug Manufacturer Market Share
3.4.2 Top 6 Prophylactic HIV Drug Manufacturer Market Share
3.5 Global Prophylactic HIV Drug Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Prophylactic HIV Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Prophylactic HIV Drug Market Size by Region
4.1.1 Global Prophylactic HIV Drug Sales in Volume by Region (2016-2026)
4.1.2 Global Prophylactic HIV Drug Revenue by Region (2016-2026)
4.2 North America Prophylactic HIV Drug Revenue (2016-2026)
4.3 Europe Prophylactic HIV Drug Revenue (2016-2026)
4.4 Asia-Pacific Prophylactic HIV Drug Revenue (2016-2026)
4.5 South America Prophylactic HIV Drug Revenue (2016-2026)
4.6 Middle East and Africa Prophylactic HIV Drug Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Prophylactic HIV Drug Sales in Volume by Type (2016-2026)
5.2 Global Prophylactic HIV Drug Revenue by Type (2016-2026)
5.3 Global Prophylactic HIV Drug Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Prophylactic HIV Drug Sales in Volume by Application (2016-2026)
6.2 Global Prophylactic HIV Drug Revenue by Application (2016-2026)
6.3 Global Prophylactic HIV Drug Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Prophylactic HIV Drug Sales by Type (2016-2026)
7.2 North America Prophylactic HIV Drug Sales by Application (2016-2026)
7.3 North America Prophylactic HIV Drug Market Size by Country
7.3.1 North America Prophylactic HIV Drug Sales in Volume by Country (2016-2026)
7.3.2 North America Prophylactic HIV Drug Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Prophylactic HIV Drug Sales by Type (2016-2026)
8.2 Europe Prophylactic HIV Drug Sales by Application (2016-2026)
8.3 Europe Prophylactic HIV Drug Market Size by Country
8.3.1 Europe Prophylactic HIV Drug Sales in Volume by Country (2016-2026)
8.3.2 Europe Prophylactic HIV Drug Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Prophylactic HIV Drug Sales by Type (2016-2026)
9.2 Asia-Pacific Prophylactic HIV Drug Sales by Application (2016-2026)
9.3 Asia-Pacific Prophylactic HIV Drug Market Size by Region
9.3.1 Asia-Pacific Prophylactic HIV Drug Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Prophylactic HIV Drug Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Prophylactic HIV Drug Sales by Type (2016-2026)
10.2 South America Prophylactic HIV Drug Sales by Application (2016-2026)
10.3 South America Prophylactic HIV Drug Market Size by Country
10.3.1 South America Prophylactic HIV Drug Sales in Volume by Country (2016-2026)
10.3.2 South America Prophylactic HIV Drug Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Prophylactic HIV Drug Sales by Type (2016-2026)
11.2 Middle East & Africa Prophylactic HIV Drug Sales by Application (2016-2026)
11.3 Middle East & Africa Prophylactic HIV Drug Market Size by Country
11.3.1 Middle East & Africa Prophylactic HIV Drug Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Prophylactic HIV Drug Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Prophylactic HIV Drug Typical Distributors
12.3 Prophylactic HIV Drug Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Prophylactic HIV Drug Revenue by Type, (USD Million), 2021-2026
Table 2. Global Prophylactic HIV Drug Revenue by Application, (USD Million), 2021-2026
Table 3. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 4. Gilead Sciences Major Business
Table 5. Gilead Sciences Prophylactic HIV Drug Product and Services
Table 6. Gilead Sciences Prophylactic HIV Drug Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Merck Basic Information, Manufacturing Base and Competitors
Table 8. Merck Major Business
Table 9. Merck Prophylactic HIV Drug Product and Services
Table 10. Merck Prophylactic HIV Drug Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Mylan Basic Information, Manufacturing Base and Competitors
Table 12. Mylan Major Business
Table 13. Mylan Prophylactic HIV Drug Product and Services
Table 14. Mylan Prophylactic HIV Drug Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Cipla Basic Information, Manufacturing Base and Competitors
Table 16. Cipla Major Business
Table 17. Cipla Prophylactic HIV Drug Product and Services
Table 18. Cipla Prophylactic HIV Drug Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 20. Bristol-Myers Squibb Major Business
Table 21. Bristol-Myers Squibb Prophylactic HIV Drug Product and Services
Table 22. Bristol-Myers Squibb Prophylactic HIV Drug Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Roche Basic Information, Manufacturing Base and Competitors
Table 24. Roche Major Business
Table 25. Roche Prophylactic HIV Drug Product and Services
Table 26. Roche Prophylactic HIV Drug Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Global Prophylactic HIV Drug Sales by Manufacturer (2019-2021e) & (K Units)
Table 28. Global Prophylactic HIV Drug Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 29. Market Position of Manufacturers in Prophylactic HIV Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 30. Global Prophylactic HIV Drug Production Capacity by Company, (K Units): 2020 VS 2021
Table 31. Head Office and Prophylactic HIV Drug Production Site of Key Manufacturer
Table 32. Global Prophylactic HIV Drug Sales by Region (2016-2021e) & (K Units)
Table 33. Global Prophylactic HIV Drug Sales by Region (2021-2026) & (K Units)
Table 34. Global Prophylactic HIV Drug Revenue by Region (2016-2021e) & (USD Million)
Table 35. Global Prophylactic HIV Drug Revenue by Region (2021-2026) & (USD Million)
Table 36. Global Prophylactic HIV Drug Sales by Type (2016-2021e) & (K Units)
Table 37. Global Prophylactic HIV Drug Sales by Type (2021-2026) & (K Units)
Table 38. Global Prophylactic HIV Drug Revenue by Type (2016-2021e) & (USD Million)
Table 39. Global Prophylactic HIV Drug Revenue by Type (2021-2026) & (USD Million)
Table 40. Global Prophylactic HIV Drug Price by Type (2016-2021e) & (USD/Unit)
Table 41. Global Prophylactic HIV Drug Price by Type (2021-2026) & (USD/Unit)
Table 42. Global Prophylactic HIV Drug Sales by Application (2016-2021e) & (K Units)
Table 43. Global Prophylactic HIV Drug Sales by Application (2021-2026) & (K Units)
Table 44. Global Prophylactic HIV Drug Revenue by Application (2016-2021e) & (USD Million)
Table 45. Global Prophylactic HIV Drug Revenue by Application (2021-2026) & (USD Million)
Table 46. Global Prophylactic HIV Drug Price by Application (2016-2021e) & (USD/Unit)
Table 47. Global Prophylactic HIV Drug Price by Application (2021-2026) & (USD/Unit)
Table 48. North America Prophylactic HIV Drug Sales by Country (2016-2021e) & (K Units)
Table 49. North America Prophylactic HIV Drug Sales by Country (2021-2026) & (K Units)
Table 50. North America Prophylactic HIV Drug Revenue by Country (2016-2021e) & (USD Million)
Table 51. North America Prophylactic HIV Drug Revenue by Country (2021-2026) & (USD Million)
Table 52. North America Prophylactic HIV Drug Sales by Type (2016-2021e) & (K Units)
Table 53. North America Prophylactic HIV Drug Sales by Type (2021-2026) & (K Units)
Table 54. North America Prophylactic HIV Drug Sales by Application (2016-2021e) & (K Units)
Table 55. North America Prophylactic HIV Drug Sales by Application (2021-2026) & (K Units)
Table 56. Europe Prophylactic HIV Drug Sales by Country (2016-2021e) & (K Units)
Table 57. Europe Prophylactic HIV Drug Sales by Country (2021-2026) & (K Units)
Table 58. Europe Prophylactic HIV Drug Revenue by Country (2016-2021e) & (USD Million)
Table 59. Europe Prophylactic HIV Drug Revenue by Country (2021-2026) & (USD Million)
Table 60. Europe Prophylactic HIV Drug Sales by Type (2016-2021e) & (K Units)
Table 61. Europe Prophylactic HIV Drug Sales by Type (2021-2026) & (K Units)
Table 62. Europe Prophylactic HIV Drug Sales by Application (2016-2021e) & (K Units)
Table 63. Europe Prophylactic HIV Drug Sales by Application (2021-2026) & (K Units)
Table 64. Asia-Pacific Prophylactic HIV Drug Sales by Region (2016-2021e) & (K Units)
Table 65. Asia-Pacific Prophylactic HIV Drug Sales by Region (2021-2026) & (K Units)
Table 66. Asia-Pacific Prophylactic HIV Drug Revenue by Region (2016-2021e) & (USD Million)
Table 67. Asia-Pacific Prophylactic HIV Drug Revenue by Region (2021-2026) & (USD Million)
Table 68. Asia-Pacific Prophylactic HIV Drug Sales by Type (2016-2021e) & (K Units)
Table 69. Asia-Pacific Prophylactic HIV Drug Sales by Type (2021-2026) & (K Units)
Table 70. Asia-Pacific Prophylactic HIV Drug Sales by Application (2016-2021e) & (K Units)
Table 71. Asia-Pacific Prophylactic HIV Drug Sales by Application (2021-2026) & (K Units)
Table 72. South America Prophylactic HIV Drug Sales by Country (2016-2021e) & (K Units)
Table 73. South America Prophylactic HIV Drug Sales by Country (2021-2026) & (K Units)
Table 74. South America Prophylactic HIV Drug Revenue by Country (2016-2021e) & (USD Million)
Table 75. South America Prophylactic HIV Drug Revenue by Country (2021-2026) & (USD Million)
Table 76. South America Prophylactic HIV Drug Sales by Type (2016-2021e) & (K Units)
Table 77. South America Prophylactic HIV Drug Sales by Type (2021-2026) & (K Units)
Table 78. South America Prophylactic HIV Drug Sales by Application (2016-2021e) & (K Units)
Table 79. South America Prophylactic HIV Drug Sales by Application (2021-2026) & (K Units)
Table 80. Middle East & Africa Prophylactic HIV Drug Sales by Country (2016-2021e) & (K Units)
Table 81. Middle East & Africa Prophylactic HIV Drug Sales by Country (2021-2026) & (K Units)
Table 82. Middle East & Africa Prophylactic HIV Drug Revenue by Country (2016-2021e) & (USD Million)
Table 83. Middle East & Africa Prophylactic HIV Drug Revenue by Country (2021-2026) & (USD Million)
Table 84. Middle East & Africa Prophylactic HIV Drug Sales by Type (2016-2021e) & (K Units)
Table 85. Middle East & Africa Prophylactic HIV Drug Sales by Type (2021-2026) & (K Units)
Table 86. Middle East & Africa Prophylactic HIV Drug Sales by Application (2016-2021e) & (K Units)
Table 87. Middle East & Africa Prophylactic HIV Drug Sales by Application (2021-2026) & (K Units)
Table 88. Direct Channel Pros & Cons
Table 89. Indirect Channel Pros & Cons
Table 90. Prophylactic HIV Drug Typical Distributors
Table 91. Prophylactic HIV Drug Typical Customers
List of Figures
Figure 1. Prophylactic HIV Drug Picture
Figure 2. Global Prophylactic HIV Drug Sales Market Share by Type in 2020
Figure 3. Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
Figure 4. Integrase Inhibitor
Figure 5. Global Prophylactic HIV Drug Sales Market Share by Application in 2020
Figure 6. Hospital Pharmacy
Figure 7. Retail Pharmacy
Figure 8. Online Pharmacy
Figure 9. Global Prophylactic HIV Drug Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 10. Global Prophylactic HIV Drug Market Size and Forecast (2016-2026) & (USD Million)
Figure 11. United States Prophylactic HIV Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 12. Canada Prophylactic HIV Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 13. Mexico Prophylactic HIV Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 14. Germany Prophylactic HIV Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 15. France Prophylactic HIV Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 16. United Kingdom Prophylactic HIV Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 17. Russia Prophylactic HIV Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 18. Italy Prophylactic HIV Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. China Prophylactic HIV Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. Japan Prophylactic HIV Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. Korea Prophylactic HIV Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. India Prophylactic HIV Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. Southeast Asia Prophylactic HIV Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. Australia Prophylactic HIV Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. Brazil Prophylactic HIV Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. Egypt Prophylactic HIV Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. Saudi Arabia Prophylactic HIV Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. South Africa Prophylactic HIV Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. Turkey Prophylactic HIV Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. Global Prophylactic HIV Drug Sales (2016-2026) & (K Units)
Figure 31. Global Prophylactic HIV Drug Production Capacity (2016-2026) & (K Units)
Figure 32. Global Prophylactic HIV Drug Production Capacity by Geographic Region: 2020 VS 2021
Figure 33. Prophylactic HIV Drug Market Drivers
Figure 34. Prophylactic HIV Drug Market Restraints
Figure 35. Prophylactic HIV Drug Market Trends
Figure 36. Global Prophylactic HIV Drug Sales Market Share by Manufacturer in 2020
Figure 37. Global Prophylactic HIV Drug Revenue Market Share by Manufacturer in 2020
Figure 38. Prophylactic HIV Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 39. Top 3 Prophylactic HIV Drug Manufacturer (Revenue) Market Share in 2020
Figure 40. Top 6 Prophylactic HIV Drug Manufacturer (Revenue) Market Share in 2020
Figure 41. Global Prophylactic HIV Drug Sales Market Share by Region (2016-2026)
Figure 42. Global Prophylactic HIV Drug Revenue Market Share by Region (2016-2026)
Figure 43. North America Prophylactic HIV Drug Revenue (2016-2026) & (USD Million)
Figure 44. Europe Prophylactic HIV Drug Revenue (2016-2026) & (USD Million)
Figure 45. Asia-Pacific Prophylactic HIV Drug Revenue (2016-2026) & (USD Million)
Figure 46. South America Prophylactic HIV Drug Revenue (2016-2026) & (USD Million)
Figure 47. Middle East & Africa Prophylactic HIV Drug Revenue (2016-2026) & (USD Million)
Figure 48. Global Prophylactic HIV Drug Sales Market Share by Type (2016-2026)
Figure 49. Global Prophylactic HIV Drug Revenue Market Share by Type (2016-2026)
Figure 50. Global Prophylactic HIV Drug Price by Type (2016-2026) & (USD/Unit)
Figure 51. Global Prophylactic HIV Drug Sales Market Share by Application (2016-2026)
Figure 52. Global Prophylactic HIV Drug Revenue Market Share by Application (2016-2026)
Figure 53. Global Prophylactic HIV Drug Price by Application (2016-2026) & (USD/Unit)
Figure 54. North America Prophylactic HIV Drug Sales Market Share by Country (2016-2026)
Figure 55. North America Prophylactic HIV Drug Revenue Market Share by Country (2016-2026)
Figure 56. North America Prophylactic HIV Drug Sales Market Share by Type (2016-2026)
Figure 57. North America Prophylactic HIV Drug Sales Market Share by Application (2016-2026)
Figure 58. Europe Prophylactic HIV Drug Sales Market Share by Country (2016-2026)
Figure 59. Europe Prophylactic HIV Drug Revenue Market Share by Country (2016-2026)
Figure 60. Europe Prophylactic HIV Drug Sales Market Share by Type (2016-2026)
Figure 61. Europe Prophylactic HIV Drug Sales Market Share by Application (2016-2026)
Figure 62. Asia-Pacific Prophylactic HIV Drug Sales Market Share by Region (2016-2026)
Figure 63. Asia-Pacific Prophylactic HIV Drug Revenue Market Share by Region (2016-2026)
Figure 64. Asia-Pacific Prophylactic HIV Drug Sales Market Share by Region (2016-2026)
Figure 65. Asia-Pacific Prophylactic HIV Drug Sales Market Share by Application (2016-2026)
Figure 66. South America Prophylactic HIV Drug Sales Market Share by Country (2016-2026)
Figure 67. South America Prophylactic HIV Drug Revenue Market Share by Country (2016-2026)
Figure 68. South America Prophylactic HIV Drug Sales Market Share by Type (2016-2026)
Figure 69. South America Prophylactic HIV Drug Sales Market Share by Application (2016-2026)
Figure 70. Middle East & Africa Prophylactic HIV Drug Sales Market Share by Country (2016-2026)
Figure 71. Middle East & Africa Prophylactic HIV Drug Revenue Market Share by Country (2016-2026)
Figure 72. Middle East & Africa Prophylactic HIV Drug Sales Market Share by Type (2016-2026)
Figure 73. Middle East & Africa Prophylactic HIV Drug Sales Market Share by Application (2016-2026)
Figure 74. Sales Channel: Direct Channel vs Indirect Channel
Figure 75. Methodology
Figure 76. Research Process and Data Source
HIV薬の世界市場予測 2023年：メーカー別、地域別、種類・用途別 HIV is a type of retrovirus that causes serious complications in humans. It generally spreads via the blood, semen, vaginal fluid, pre-ejaculate, or breast milk. The global market for HIV drugs is envisaged to surpass USD 19,000 million by 2019 owing to the recent rise in HIV patient population. Sco…- 薬物送達の世界市場2018-2025 In 2018, the global Drug Delivery market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. In this study, 2017 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Drug Delivery. This study researches t…
- 市販薬の世界市場予測 2023年：メーカー別、地域別、種類・用途別 OTC drugs are medicines that can be bought without a prescription from a doctor. Scope of the Report: This report focuses on the Over-the-Counter Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market bas…
- パーキンソン病の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Researchers are working to develop new and improved therapies for people with Parkinson's disease (PD). There have been many drugs that have been approved to treat Parkinson disease. Scope of the Report: This report focuses on the Parkinsons disease Drug in global market, especially in North America…
- 世界の抗エイズ薬市場 2021：企業別、地域別、種類・用途別 The Anti-AIDs Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, rec…